Advanced Hepatocellular Carcinoma | Unmet Need | US/EU5 | 2022

Hepatocellular carcinoma, the most common type of liver cancer, occurs as a result of chronic liver cirrhosis. It has a five-year survival rate of only 18%. First-line advanced hepatocellular carcinoma is the largest drug-treatable hepatocellular carcinoma population and thus the most commercially lucrative for drug developers. This therapy market will experience rapid growth, driven by the approval of immune checkpoint inhibitors and combination therapies such as Tecentriq plus bevacizumab and Opdivo plus Yervoy. In this report, we analyze the factors that influence the prescribing decisions of medical oncologists treating advanced hepatocellular carcinoma and review the unmet needs that novel therapies should target.

QUESTIONS ANSWERED

• What are the treatment drivers and goals associated with advanced hepatocellular carcinoma?
• How do immune checkpoint inhibitors in combination with angiogenesis inhibitors (e.g., Roche’s Tecentriq plus bevacizumab) or double-agent immune checkpoint inhibitors (e.g., Bristol Myers Squibb’s Opdivo plus Yervoy) perform on key treatment drivers and goals in advanced hepatocellular carcinoma?
• What are the prevailing areas of unmet need and opportunity in the treatment of advanced hepatocellular carcinoma?
• What trade-offs across different clinical attributes and prices are acceptable to U.S. and European medical oncologists for a hypothetical new drug for advanced hepatocellular carcinoma?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease subpopulation. Based on the surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 61 U.S. and 33 European medical oncologists fielded in December 2021

Key companies: Bayer, Eisai, Exelixis / Ipsen, Eli Lilly, Roche / Genentech, Merck & Co., Bristol Myers Squibb

Key drugs: Nexavar, Lenvima, Cabometyx, Cyramza, Opdivo + Yervoy, Keytruda, and Tecentriq + bevacizumab